Successful resolution of pneumonia developed in a patient affected by Crohn's disease, rheumatoid arthritis, myasthenia gravis and recurrent uveitis during concomitant treatment with tumour necrosis factor α inhibitors and conventional immunosuppressive drugs

Erika Angelucci (1) , Monica Cesarini (1) , Piero Vernia (1)

1 Gastroenterology Unit

Tumour necrosis factor alpha inhibitors, both infliximab and adalimumab, have been approved for the treatment of both rheumatoid arthritis and Crohn's disease. A slight increase in the risk of infections in patients receiving immunosuppressants and/or biological agents has been reported. Here, we present the case of a 68-year-old woman affected by Crohn's disease, myasthenia gravis, recurrent uveitis and rheumatoid arthritis who developed pneumonia during concomitant treatment with biological agents and conventional immunosuppressive drugs.

Mots clés: Crohn's disease; Rheumatoid arthritis; Tumour necrosis factor alpha inhibitors

Erika Angelucci, Monica Cesarini, Piero Vernia. Successful resolution of pneumonia developed in a patient affected by Crohn's disease, rheumatoid arthritis, myasthenia gravis and recurrent uveitis during concomitant treatment with tumour necrosis factor α inhibitors and conventional immunosuppressive drugs. Rheumatology International, 2009, 30 (7), pp.977-978. ⟨10.1007/s00296-009-1012-6⟩. ⟨hal-00568299⟩